neuroprotection – Page 5

Polysorbate 80 Differentially Impacts Erinacine Production Profiles in Submerged Cultures of Hericium

mycolabadmin

Lion’s mane mushroom and related Hericium species produce beneficial compounds called erinacines that may protect the brain and help with neurological conditions. This study tested how adding glucose and a substance called polysorbate 80 to mushroom cultures affects erinacine production. Interestingly, while polysorbate 80 helped mushrooms grow more, it reduced erinacine levels in most strains, though effects varied by species. The findings could help cultivators choose conditions to grow mushrooms enriched with specific beneficial compounds.

New Positive TRPC6 Modulator Penetrates Blood–Brain Barrier, Eliminates Synaptic Deficiency and Restores Memory Deficit in 5xFAD Mice

mycolabadmin

Researchers developed a new drug candidate called C20 that activates TRPC6 proteins in the brain. In studies with Alzheimer’s disease mouse models, C20 protected nerve connections from damage, restored memory function, and successfully crossed the blood-brain barrier. The compound shows promise as a potential treatment for Alzheimer’s disease by strengthening the connections between brain cells that are damaged in the disease.

The progress of the microbe-gut-brain axis in sepsis-associated encephalopathy

mycolabadmin

Sepsis can cause brain dysfunction called sepsis-associated encephalopathy, leading to memory problems and confusion in about one-third to two-thirds of sepsis patients. The bacteria in your gut communicate with your brain through multiple pathways, and when sepsis disrupts this communication, it causes harmful inflammation in the brain. Treatments like probiotics and transplanting healthy gut bacteria from donors show promise in animal studies and early human trials for improving memory and cognitive function after sepsis.

Evaluating the antioxidant, anti-inflammatory, and neuroprotective potential of fruiting body and mycelium extracts from edible yellow morel (Morchella esculenta L. Pers.)

mycolabadmin

This study examined morel mushrooms from Pakistan to see if they could help treat Alzheimer’s disease and related brain conditions. Researchers tested both the fruiting bodies and the root-like mycelia of Morchella esculenta mushrooms for their ability to fight oxidative stress, reduce inflammation, and inhibit an enzyme that breaks down acetylcholine, a brain chemical important for memory. The results showed that morel extracts, especially from fruiting bodies collected in certain regions, worked as well as or better than conventional medications, suggesting these common edible mushrooms could be developed into treatments for neurodegenerative diseases.

Comparative transcriptome analysis reveals the genetic basis underlying the biosynthesis of polysaccharides in Hericium erinaceus

mycolabadmin

Researchers studied six different strains of lion’s mane mushrooms to understand how they produce beneficial compounds called polysaccharides. Using advanced genetic analysis, they identified thirteen key genes responsible for making these health-promoting molecules. The study found that a strain called PZH-05 produced the most polysaccharides, and its genes were more active than in other strains. This research helps explain why lion’s mane mushrooms are effective for boosting immunity, fighting cancer, and managing blood sugar.

Identification of potential neuroprotective compound from Ganoderma lucidum extract targeting microtubule affinity regulation kinase 4 involved in Alzheimer’s disease through molecular dynamics simulation and MMGBSA

mycolabadmin

Researchers used computer simulations to test five compounds from Reishi mushrooms against Alzheimer’s disease. They found that two compounds, ganoderic acid A and ganoderenic acid B, showed strong potential for blocking a harmful protein involved in the disease. These findings suggest Reishi mushrooms could be a source for new Alzheimer’s treatments, though further laboratory testing is needed.

Immunomodulatory natural polysaccharide-based nanoparticles for the treatment of neurodegenerative diseases

mycolabadmin

Scientists are developing tiny particles made from natural sugar-based compounds that can deliver medicine to the brain while reducing inflammation caused by neurodegenerative diseases like Alzheimer’s and Parkinson’s. These nanoparticles are special because they can cross the protective barrier surrounding the brain and carry therapeutic compounds directly to where they’re needed. The natural polysaccharides used to make these particles have built-in anti-inflammatory properties, making them safer and more effective than traditional approaches. This innovative technology shows promise for treating currently difficult-to-manage brain diseases.

Reprogramming astrocytic NDRG2/NF-κB/C3 signaling restores the diabetes-associated cognitive dysfunction

mycolabadmin

This study found that regular exercise helps protect the brain of diabetic people from cognitive decline by boosting a protein called NDRG2 in astrocytes (brain support cells). The research shows that NDRG2 works by blocking harmful immune responses that damage synapses (connections between brain cells). In diabetic mice, exercise improved memory and learning ability while increasing NDRG2 levels, while blocking this protein reversed these benefits.

therapeutic action: neuroprotection